NASDAQ:ADXS - Advaxis Stock Price, Forecast & News

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Advaxis, Inc. (NASDAQ:ADXS) announced its earnings results on Tuesday, March, 12th. The biotechnology company reported $0.18 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.25) by $0.43. The biotechnology company earned $19.69 million during the quarter. Advaxis had a negative net margin of 79.31% and a negative return on equity of 40.98%. View Advaxis' Earnings History.

Advaxis is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Advaxis.

1 brokerages have issued 12 month price targets for Advaxis' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Advaxis' stock price to reach $4.00 in the next year. This suggests a possible upside of 348.7% from the stock's current price. View Analyst Price Targets for Advaxis.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.

Media coverage about ADXS stock has been trending very negative on Saturday, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Advaxis.

Some companies that are related to Advaxis include Aridis Pharmaceuticals (ARDS), Entasis Therapeutics (ETTX), Aclaris Therapeutics (ACRS), Sunesis Pharmaceuticals (SNSS), Kezar Life Sciences (KZR), Acasti Pharma (ACST), Soligenix (SNGX), Alpine Immune Sciences (ALPN), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), resTORbio (TORC), Vascular Biogenics (VBLT), DiaMedica Therapeutics (DMAC), SUMMIT THERAPEU/S (SMMT) and Hoth Therapeutics (HOTH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Anavex Life Sciences (AVXL), Celgene (CELG), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), Novavax (NVAX) and ContraVir Pharmaceuticals (CTRV).

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADXS stock can currently be purchased for approximately $0.89.

Advaxis has a market capitalization of $15.35 million and generates $20.88 million in revenue each year. The biotechnology company earns $-16,610,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.

The official website for Advaxis is http://www.advaxis.com/.

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]